Revance Therapeutics Inc. (NASDAQ:RVNC) shares rose 2.9% during mid-day trading on Thursday . The company traded as high as $15.42 and last traded at $15.30, with a volume of 53,315 shares trading hands. The stock had previously closed at $14.87.

RVNC has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 13th. Brean Capital restated a “buy” rating and set a $48.00 price target on shares of Revance Therapeutics in a research note on Tuesday, May 24th. Guggenheim restated a “buy” rating and set a $55.00 price target on shares of Revance Therapeutics in a research note on Tuesday, June 14th. Finally, SunTrust Banks Inc. dropped their price objective on shares of Revance Therapeutics from $46.00 to $22.00 and set a “buy” rating on the stock in a report on Tuesday, June 14th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Revance Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $39.60.

The stock’s market cap is $430.11 million. The stock has a 50 day moving average price of $13.88 and a 200 day moving average price of $16.83.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.02. The company had revenue of $0.80 million for the quarter, compared to the consensus estimate of $0.06 million. The firm’s quarterly revenue was up .0% on a year-over-year basis. On average, analysts anticipate that Revance Therapeutics Inc. will post ($3.53) EPS for the current fiscal year.

Revance Therapeutics, Inc is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.